echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > NEJM: The risk of myocarditis after BNT162b2 mRNA vaccination is 2.13 cases per 100,000 people

    NEJM: The risk of myocarditis after BNT162b2 mRNA vaccination is 2.13 cases per 100,000 people

    • Last Update: 2021-12-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    In Israel, 2020 December 20 start nationwide new crown pneumonia mRNA vaccine (BNT162b2) vaccination, as of May 5, 2021, 58.
    2% of the Israeli population vaccinated with at least one vaccine, 54.
    6% had completed 2 vaccinations
    .


    On May 27, 2021, the Centers for Disease Control and Prevention (CDC) issued a statement stating that the BNT162b2 vaccine and mRNA-1273 vaccine may be associated with the risk of myocarditis


    New coronary pneumonia prevention Recently, researchers have systematically studied the risk of myocarditis in vaccinating the new coronary pneumonia mRNA vaccine


    The researchers searched Israel's largest health care organization (HCO)-Clalit health service organization database data, looking for patients with myocarditis diagnosed after receiving at least one dose of the BNT162b2 vaccine.
    The diagnosis of myocarditis was made by a professional doctor
    .


    The clinical manifestations, course and results are extracted from the electronic health records of the patients


    diagnosis

    The HCO database contains data on 2.
    5 million vaccinated populations over 16 years old, and 54 of them have been diagnosed with myocarditis
    .


    After vaccination with at least one dose of the vaccine, there were 2.


    After vaccination with at least one dose of the vaccine, there were 2.


    Cumulative myocarditis events 42 days after vaccination

    Cumulative myocarditis events 42 days after vaccination Cumulative myocarditis events 42 days after vaccination

    The study found that in people who received at least one dose of BNT162b2 mRNA vaccine, the incidence of myocarditis was 2.
    13 cases per 100,000 people.
    Among them, people aged 16-29 had the highest risk, and most cases of myositis were mild or moderate
    .

    In people who received at least one dose of BNT162b2 mRNA vaccine, the incidence of myocarditis was 2.
    13 cases per 100,000 people.
    Among them, people aged 16-29 had the highest risk, and most cases of myositis were mild or moderate
    .


    In people who received at least one dose of BNT162b2 mRNA vaccine, the incidence of myocarditis was 2.


    Guy Witberg et al.


    Myocarditis after Covid-19 Vaccination in a Large Health Care Organization.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.